[Federal Register Volume 88, Number 16 (Wednesday, January 25, 2023)]
[Notices]
[Page 4833]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-01416]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Amy F. Petrik, Ph.D., 240-627-3721; 
[email protected]. Licensing information and copies of the U.S. patent 
application listed below may be obtained by communicating with the 
indicated licensing contact at the Technology Transfer and Intellectual 
Property Office, National Institute of Allergy and Infectious Diseases, 
5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed 
Confidential Disclosure Agreement will be required to receive copies of 
unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows:

Antibodies With Potent and Broad Neutralizing Activity Against 
Antigenically Diverse and Highly Transmissible SARS-CoV-2 Variants

    Description of Technology: Emergence of highly transmissible SARS-
CoV-2 variants of concern that are resistant to current therapeutic 
antibodies highlights the need for continuing discovery of broadly 
reactive antibodies.
    Scientists at the Vaccine Research Center of the National Institute 
of Allergy and Infectious Diseases have identified multiple antibodies 
that ultra-potently neutralize SARS-CoV-2, including the highly 
transmissible BA.4, BA.5, BQ.1.1 and XBB subvariants of Omicron, as 
shown in a pseudovirus neutralization assay. These antibodies target 
several epitopes in the receptor binding domain of the spike protein 
that are not impacted by spike mutations that knockout binding to other 
therapeutic antibodies, including, K417N, N439K, N440K, K444T, V445P, 
G446S, L452R, Y453F, N460K, S477N, E484A/K, F486S/V and Q498R. Several 
of the antibodies are able to simultaneously bind to the spike protein 
and are compatible for use in combination therapies.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404.
    Potential Commercial Applications:

 Treatment of SARS-CoV-2 infection
    Competitive Advantages:

 Ultra-potent neutralization of currently identified SARS-CoV-2 
variants including Omicron subvariants BQ.1.1 and XBB
 Mechanism of Action--Some antibodies directly bind to and 
block ACE2 receptor binding to the SARS-CoV-2 spike protein

    Development Stage: Preclinical Research.
    Inventors: John Misasi (VRC, NIAID), Lingshu Wang (VRC, NIAID), 
John Mascola (VRC, NIAID), Daniel Douek (VRC, NIAID), Nancy Sullivan 
(VRC, NIAID), Richard Alan Koup (VRC, NIAID), Man Chen, (VRC, NIAID), 
Wei Shi (VRC, NIAID), Yi Zhang (VRC, NIAID), Eun Sung Yang (VRC, 
NIAID), Nicole Doria-Rose (VRC, NIAID), Chaim Schramm (VRC, NIAID), 
Kevina Maria Nabireka Birungi-Huff (VRC, NIAID), Sabrina Bush (VRC, 
NIAID), Maryam Musayev (VRC, NIAID).
    Publications: None.
    Intellectual Property: HHS Reference Number E-024-2023 includes 
U.S. Provisional Patent Application Number 63/433,719 filed December 
19, 2022.
    Licensing Contact: To license this technology, please contact Amy 
F. Petrik, Ph.D., 240-627-3721; [email protected].

    Dated: January 19, 2023.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2023-01416 Filed 1-24-23; 8:45 am]
BILLING CODE 4140-01-P